Therefore, these results support the view that changes in SM levels, possibly also due to altered Cer trafficking by CERT, might suggest novel strategies for inducing BC cell death or attenuating drug resistance, and that CERT could be a new pharmacological target in cancer resistant to chemotherapy. The gene discussed is CBLN1; the disease is breast cancer.